HK1254293A1 - 一種重組單純皰疹病毒及其用途 - Google Patents

一種重組單純皰疹病毒及其用途

Info

Publication number
HK1254293A1
HK1254293A1 HK18113254.4A HK18113254A HK1254293A1 HK 1254293 A1 HK1254293 A1 HK 1254293A1 HK 18113254 A HK18113254 A HK 18113254A HK 1254293 A1 HK1254293 A1 HK 1254293A1
Authority
HK
Hong Kong
Prior art keywords
herpes simplex
simplex virus
recombinant herpes
recombinant
virus
Prior art date
Application number
HK18113254.4A
Other languages
English (en)
Inventor
黃承浩
羅勇
袁權
張軍
夏寧邵
Original Assignee
廈門大學
北京萬泰生物藥業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 廈門大學, 北京萬泰生物藥業股份有限公司 filed Critical 廈門大學
Publication of HK1254293A1 publication Critical patent/HK1254293A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/035—Herpes simplex virus I or II
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18113254.4A 2017-03-09 2018-10-16 一種重組單純皰疹病毒及其用途 HK1254293A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710136638 2017-03-09
CN201710301464 2017-05-02

Publications (1)

Publication Number Publication Date
HK1254293A1 true HK1254293A1 (zh) 2019-07-19

Family

ID=63447188

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18113254.4A HK1254293A1 (zh) 2017-03-09 2018-10-16 一種重組單純皰疹病毒及其用途

Country Status (11)

Country Link
US (1) US11680248B2 (zh)
JP (2) JP7490365B2 (zh)
KR (1) KR102227180B1 (zh)
CN (2) CN108570455B (zh)
AU (1) AU2018230046B9 (zh)
BR (1) BR112019018630A2 (zh)
CA (1) CA3055627A1 (zh)
HK (1) HK1254293A1 (zh)
MY (1) MY197423A (zh)
TW (2) TWI839805B (zh)
WO (1) WO2018161825A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108570455B (zh) * 2017-03-09 2022-08-12 厦门大学 一种重组单纯疱疹病毒及其用途
CN109679928B (zh) * 2018-12-19 2019-12-10 重庆点检生物科技有限公司 重组单纯疱疹病毒、试剂盒及其用途
EP3938524A1 (en) * 2019-03-14 2022-01-19 Massachusetts Institute of Technology Engineered herpes simplex virus-1 (hsv-1) vectors and uses thereof
SG11202109707VA (en) * 2019-03-14 2021-10-28 Res Inst Nationwide Childrens Hospital Syncytial oncolytic herpes simplex mutants as potent cancer therapeutics
CN114761030A (zh) * 2019-11-01 2022-07-15 休斯敦系统大学 具有诱导的抗肿瘤免疫的溶瘤病毒疗法
JP2023502099A (ja) * 2019-11-18 2023-01-20 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド コドン最適化された新世代の調節可能な融合性腫瘍溶解性単純ヘルペスウイルス１型ウイルスおよび使用方法
WO2021175293A1 (zh) * 2020-03-05 2021-09-10 北京唯源立康生物科技有限公司 一种单纯疱疹病毒及其用途
CN111849910B (zh) * 2020-05-27 2021-06-15 南京北恒生物科技有限公司 工程化免疫细胞及其用途
CN111635913B (zh) * 2020-06-16 2022-03-04 广东东阳光药业有限公司 构建体及其应用
CN114075574A (zh) * 2020-08-19 2022-02-22 广东东阳光药业有限公司 构建体、溶瘤病毒及其应用
CN112501137B (zh) * 2020-11-11 2023-10-20 深圳先进技术研究院 一种神经环路标记系统
CN112725471B (zh) * 2021-03-12 2022-09-16 中国大熊猫保护研究中心 野化培训大熊猫免疫适应的分子标记评估方法
WO2022212289A1 (en) * 2021-03-29 2022-10-06 Rational Vaccines, Inc. Mutant herpesvirus and vaccine compositions
CN113416741B (zh) * 2021-06-22 2022-09-27 中国科学院武汉病毒研究所 调控gK蛋白功能的顺行跨单级神经示踪系统
WO2023020598A1 (zh) * 2021-08-20 2023-02-23 广东东阳光药业有限公司 Hsv病毒载体及其应用
CN114107230B (zh) * 2021-11-29 2023-08-11 东北农业大学 一种牛疱疹病毒1型ul41缺失毒株及其获取方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9615794D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
US6277621B1 (en) * 1998-02-26 2001-08-21 Medigene, Inc. Artificial chromosome constructs containing foreign nucleic acid sequences
US6573090B1 (en) * 1998-12-09 2003-06-03 The General Hospital Corporation Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors
GB0001476D0 (en) * 2000-01-21 2000-03-15 Neurovex Ltd Herpes virus strains
WO2006002394A2 (en) * 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
CA2613310C (en) * 2005-06-23 2014-06-17 Baylor College Of Medicine Use of mutant herpes simplex virus-2 for cancer therapy
US9085777B2 (en) * 2006-05-11 2015-07-21 Virttu Biologics Limited Mutant HSV, materials and methods for generation of mutant HSV
US20080008686A1 (en) 2006-07-10 2008-01-10 The Brigham And Women's Hospital, Inc. Tetracycline repressor regulated oncolytic viruses
US8450106B2 (en) * 2007-10-17 2013-05-28 The Ohio State University Research Foundation Oncolytic virus
CN101338302B (zh) * 2008-05-04 2011-06-01 罗益（无锡）生物制药有限公司 一种用于肿瘤基因治疗的重组单纯疱疹病毒
PT2516629T (pt) * 2009-12-21 2016-07-07 The Brigham And Women`S Hospital Inc Vacinas de vírus herpes simplex
CN102220292B (zh) 2010-04-15 2014-08-27 中国医学科学院肿瘤研究所 重组ii型单纯疱疹病毒、其制备方法及应用和肿瘤诊断试剂盒
EP2877572B1 (en) * 2012-07-24 2018-11-28 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
KR102649583B1 (ko) * 2013-07-17 2024-03-20 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 효율적인 유전자 전달 적용을 위한 비독성 hsv 벡터 및 이의 생산을 위한 보완 세포
PT3184641T (pt) * 2013-10-28 2020-08-21 Univ Pittsburgh Commonwealth Sys Higher Education Vetor de hsv oncolítico
CN103910434B (zh) 2014-04-25 2015-09-02 厦门大学 用于处理沼液超标氮磷的膜式光生物反应器及其处理方法
CN105622753B (zh) * 2014-11-04 2019-04-09 博生吉医药科技(苏州)有限公司 一种pd-1单克隆抗体及其应用
GB201504251D0 (en) * 2015-03-13 2015-04-29 Virttu Biolog Ltd And University Of Sheffield The Oncolytic herpes simplex virus infected cells
WO2017189754A1 (en) * 2016-04-26 2017-11-02 Salk Institute For Biological Studies Hsv--1 oncolytic virus therapies that specificallyh kill alt dependent cancers
CN107541507A (zh) 2016-06-29 2018-01-05 厦门大学 一种rna反转录扩增方法
ES2972406T3 (es) * 2016-08-01 2024-06-12 Virogin Biotech Canada Ltd Vectores del virus oncolítico del herpes simple que expresan moléculas estimuladoras del sistema inmunitario
CN108570455B (zh) * 2017-03-09 2022-08-12 厦门大学 一种重组单纯疱疹病毒及其用途
US20220002680A1 (en) 2018-11-19 2022-01-06 The Brigham And Women's Hospital, Inc. Regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use

Also Published As

Publication number Publication date
BR112019018630A2 (pt) 2020-04-28
AU2018230046B2 (en) 2024-01-18
CA3055627A1 (en) 2018-09-13
CN115820571A (zh) 2023-03-21
KR102227180B1 (ko) 2021-03-12
AU2018230046A1 (en) 2019-10-17
JP2020511160A (ja) 2020-04-16
CN108570455B (zh) 2022-08-12
AU2018230046B9 (en) 2024-02-15
WO2018161825A1 (zh) 2018-09-13
TWI776858B (zh) 2022-09-11
KR20190140915A (ko) 2019-12-20
JP7490365B2 (ja) 2024-05-27
MY197423A (en) 2023-06-16
TW201835327A (zh) 2018-10-01
CN108570455A (zh) 2018-09-25
JP2022130531A (ja) 2022-09-06
TWI839805B (zh) 2024-04-21
US20200071679A1 (en) 2020-03-05
US11680248B2 (en) 2023-06-20
TW202246495A (zh) 2022-12-01

Similar Documents

Publication Publication Date Title
HK1254293A1 (zh) 一種重組單純皰疹病毒及其用途
EP3641810A4 (en) VACCINES AGAINST HERPES SIMPLEX VIRUS
IL258833A (en) Make simple shingles virus
EP3526332C0 (en) RECOMBINANT REPLICON SYSTEM OF VIRUSES AND THEIR USES
EP3668520A4 (en) MODIFIED RNA VACCINES CODING FOR HERPES SIMPLEX VIRUS GLYCOPROTEINS AND THEIR USES
GB201705750D0 (en) Peptide ligase and use therof
EP3453401A4 (en) INTERLEUKIN COMBINATION AND THEIR USE
IL280854A (en) Recombinant myxoma viruses and their use
EP3640327A4 (en) RECOMBINANT HERPES SIMPLEX VIRUS, MANUFACTURING METHOD FOR IT AND APPLICATION OF IT
ZA201708218B (en) Recombinant yeast and use thereof
SG11201900439XA (en) Recombinant vaccinia virus and use thereof
EP3113801A4 (en) Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
HK1257191A1 (zh) 重組火雞疱疹病毒疫苗及其用途
IL288233A (en) Modified viral particles and their use
HK1258093A1 (zh) 病毒新表位及其用途
SG11202006669RA (en) Peptides and uses thereof
ZA202104244B (en) Recombinant viruses and the uses thereof
HK1255099A1 (zh) 重組溶瘤病毒及其用途
GB201520345D0 (en) Herpes simplex viruses
EP3597759A4 (en) BORNA VIRAL VECTOR AND ITS USE
EP3947418C0 (en) PEPTIDES AND THEIR USE
EP3594328A4 (en) RECOMBINANT HERPES SIMPLEX VIRUS AND RELATED USE
IL287503A (en) Thio-semicarbazide compounds and their use
PL3250234T3 (pl) Rekombinowany mdv1 i jego zastosowania
EP3897691A4 (en) IL-10 VACCINES AND THEIR USES